Great CPC: Metformin toxicity
3.5 out of 5 stars
Case 23-2013: a 54-Year-old Woman with Abdominal Pain, Vomiting, and Confusion. Kalantar-Zadeh K et al. N Engl J Med 2013 Jul 25;369:374-382.
Full Text
This is a very instructive case discussion from the Massachusetts General Hospital. A plane was diverted to Boston because one passenger, a 54-year-old woman, developed increasing abdominal pain and vomiting, along with decreasing mental status. After the plane landed, EMS found that here vital signs were fairly unremarkable (HR = 52 bpm). She was not hypoglycemic.
Her medical history included type-2 diabetes, hypertension, and chronic renal disease. Med...
Source: The Poison Review - July 26, 2013 Category: Toxicology Authors: Leon Tags: Medical acute pancreatitis anion gap metabolic acidosis case discussion case records of the massachusetts general hospital metformin toxicity Source Type: news
More Data Will Inform Place of SGLT2 Inhibitors in DiabetesMore Data Will Inform Place of SGLT2 Inhibitors in Diabetes
A comparison of canagliflozin with glimepiride as an add-on to metformin in type 2 diabetes adds some knowledge to help guide use of the new SGLT2 inhibitors. But more will be needed, says an editorial. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes And Mild Renal Impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA® (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with Type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia, and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2013 Category: Global & Universal Source Type: news
